glp 1 polycystic kidney disease Glucagon-like peptide-1 receptor agonists in diabetic disease: A review of their kidney and heart protection Therapeutic Potential of Glucagon-like Peptide-1

New antidiabetic drugs role in the management of testosterone deficiency and of the cardiovascular disease in hypogonadal diabetic men Metab Target Organ Damage 2023;3:8

Easy measuring: At ~1.67 mg/mL, 1 unit 16.7 mcg on a U-100 syringe, so 300 mcg 18 units and 500 mcg 30 units

In some cases, aspiration of the bursa may be performed to relieve pressure and analyze the fluid for signs of infection or other underlying issues

While both agents struggled with the inherent GI burden typical of GLP-1RAs, efpeglenatides limitations were largely dose-related and within manageable expectations, whereas taspoglutides combination of severe immunogenicity and hypersensitivity reactions rendered it clinically unviable